J&J’s Doribax Is Subject Of FDA’s First "Complete Response" To An NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA is seeking additional information on Johnson & Johnson's Doribax (doripenem) prior to approving the antibiotic for the treatment of hospital-acquired pneumonia, including ventilator-associated pneumonia, the company announced Aug. 21
You may also be interested in...
J&J's Paliperidone Gets "Complete Response" Letter From FDA
No more studies are required, but FDA outlined questions that need to be addressed, according to J&J
J&J's Paliperidone Gets "Complete Response" Letter From FDA
No more studies are required, but FDA outlined questions that need to be addressed, according to J&J
Tracking Troubled NDAs: New FDA Regs Mean Less Clarity For Investors
After an 11-year process, FDA is doing away with “approvable” and “not approvable” letters. The new name (“complete response”) gets rid of the negative connotations of “not approvable.” But it is likely to create more confusion – and less transparency – for investors and the public